title: Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
abstract: BACKGROUND
  Psoriasis has substantial psychological and emotional effects. We assessed the effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue and symptoms of depression associated with the condition.
  
  
  METHODS
  618 patients with moderate to severe psoriasis received double-blind treatment with placebo or 50 mg twice-weekly etanercept. The primary efficacy endpoint was a 75% or greater improvement from baseline in psoriasis area and severity index score (PASI 75) at week 12. Secondary and other endpoints included the functional assessment of chronic illness therapy fatigue (FACIT-F) scale, the Hamilton rating scale for depression (Ham-D), the Beck depression inventory (BDI), and adverse events. Efficacy analyses were based on the allocated treatment. Analyses and summaries of safety data were based on the actual treatment received. This study is registered with with the identifier NCT00111449.
  
  
  RESULTS
  47% (147 of 311) of patients achieved PASI 75 at week 12, compared with 5% (15 of 306) of those receiving placebo (p<0.0001; difference 42%, 95% CI 36-48). Greater proportions of patients receiving etanercept had at least a 50% improvement in Ham-D or BDI at week 12 compared with the placebo group; patients treated with etanercept also had significant and clinically meaningful improvements in fatigue (mean FACIT-F improvement 5.0 vs 1.9; p<0.0001, difference 3.0, 95% CI 1.6-4.5). Improvements in fatigue were correlated with decreasing joint pain, whereas improvements in symptoms of depression were less correlated with objective measures of skin clearance or joint pain.
  
  
  CONCLUSIONS
  Etanercept treatment might relieve fatigue and symptoms of depression associated with this chronic disease.
authors.affiliation: Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Tyring
authors.forename: Alice
authors.initials: A
authors.lastname: Gottlieb
authors.forename: Kim
authors.initials: K
authors.lastname: Papp
authors.forename: Ken
authors.initials: K
authors.lastname: Gordon
authors.forename: Craig
authors.initials: C
authors.lastname: Leonardi
authors.forename: Andrea
authors.initials: A
authors.lastname: Wang
authors.forename: Deepa
authors.initials: D
authors.lastname: Lalla
authors.forename: Michael
authors.initials: M
authors.lastname: Woolley
authors.forename: Angelika
authors.initials: A
authors.lastname: Jahreis
authors.forename: Ralph
authors.initials: R
authors.lastname: Zitnik
authors.forename: David
authors.initials: D
authors.lastname: Cella
authors.forename: Ranga
authors.initials: R
authors.lastname: Krishnan
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy / Q000209:etiology*; D004311:Double-Blind Method; D000068800:Etanercept; D005221:Fatigue / Q000145:classification / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000145:classification / Q000188:drug therapy* / Q000523:psychology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept